Capivasertib
- Generic Name
- Capivasertib
- Brand Names
- Truqap
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25ClN6O2
- CAS Number
- 1143532-39-1
- Unique Ingredient Identifier
- WFR23M21IE
- Background
Capivasertib has been investigated for the treatment of Metastatic Breast Cancer.
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Conditions
- PIK3CA MutationHER2- Negative Breast CancerHormone Receptor Positive TumorBreast CancerMetastatic Breast CancerAdvanced Breast Cancer
- Interventions
- First Posted Date
- 2025-05-21
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Relay Therapeutics, Inc.
- Target Recruit Count
- 540
- Registration Number
- NCT06982521
A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain
- Conditions
- Locally Advanced or Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2025-01-08
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT06764186
- Locations
- 🇪🇸
Research Site, Zaragoza, Spain
Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients
- First Posted Date
- 2024-10-10
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 560
- Registration Number
- NCT06635447
- Locations
- 🇨🇳
Research Site, Zhengzhou, China
Effect of Capivasertib on ctDNA in ER Positive Breast Cancer
- Conditions
- Breast CancerOestrogen Receptor Positive Breast Cancer
- Interventions
- First Posted Date
- 2024-09-26
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 20
- Registration Number
- NCT06613516
- Locations
- 🇬🇧
Imperial College Healthcare Trust, London, United Kingdom
Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer
- Conditions
- CCCA Assessed by Ki67 Drop Below <2.7% From Baseline
- Interventions
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- GBG Forschungs GmbH
- Target Recruit Count
- 120
- Registration Number
- NCT06607757
- Locations
- 🇩🇪
Hämato-Onkologie im Medicum - Onkologie und Hämatologie, Bremen, Germany
🇩🇪Carl-Thiem-Klinikum gGmbH - Frauenklinik, Cottbus, Germany
🇩🇪Kath. St. Paulus GmbH - Klinische Forschung, Dortmund, Germany
Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC
- Conditions
- Metastatic Breast CancerPremenopausal Breast CancerER Positive Breast Cancer
- Interventions
- First Posted Date
- 2023-02-09
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT05720260
- Locations
- 🇨🇳
Department of Oncology, National Taiwan University Hospital, Taipei City, Taiwan
A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss
- Conditions
- High-Risk Prostate Cancer
- Interventions
- First Posted Date
- 2022-10-25
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 30
- Registration Number
- NCT05593497
- Locations
- 🇺🇸
Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina, United States
🇺🇸VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States
🇺🇸James J. Peters VA Medical Center, Bronx, NY, Bronx, New York, United States
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
- Conditions
- Breast CancerMetastatic Breast Cancer
- Interventions
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Stemline Therapeutics, Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT05563220
- Locations
- 🇺🇸
Dothan Hematology and Oncology, Dothan, Alabama, United States
🇺🇸Mayo Clinic - Arizona, Phoenix, Arizona, United States
🇺🇸Highlands Oncology Group, Springdale, Arkansas, United States
A Study to Investigate the Absolute Bioavailability, Absorption, Metabolism, Distribution and Excretion of [14C]AZD5363 (Capivasertib)
- Conditions
- Healthy Volunteer
- Interventions
- Drug: [14C]AZD5363 (Capivasertib)
- First Posted Date
- 2022-06-15
- Last Posted Date
- 2022-07-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 7
- Registration Number
- NCT05419401
- Locations
- 🇬🇧
Research Site, Ruddington, United Kingdom
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2022-04-27
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1035
- Registration Number
- NCT05348577
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.